Anzeige
Mehr »
Login
Freitag, 10.07.2020 Börsentäglich über 12.000 News von 632 internationalen Medien
Massive Expansion im Gold-District: Fliegt jetzt der Deckel weg?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Endpoints News

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
12:35Nick Galakatos and the Blackstone team now have a record $4.6B to invest in biopharma, with a big focus on pushing companies over the top
DoAfter psilocybin and ketamine, a new biotech comes along developing a drug Scott Gottlieb tried to ban
DoBiopharma companies pledge $1B to fund antibiotics R&D as field shrivels; Four biotechs hunt $797M+
DoForbion spotlights late-stage plays, carves out new €250M growth fund
DoMerck expands scope of Zymeworks antibody alliance, adding close to $900M in milestones
DoThe home run count: The $100M+ mega-round boom in biotech inspired a $6.7B feeding frenzy - so far this year
DoNIH kicks off Covid-19 vaccine, monoclonal antibody research network
DoStanford star oncology scientist Ed Engleman helped create the immunotherapy field. Now he wants to shake up neurodegeneration R&D
DoOut to revive R&D, a resurgent Sanofi pays $150M cash to partner up with a pioneering protein degradation player
DoAnother biotech IPO set-up? Multinational biotech leaps from round to round, scooping up cash at a blistering pace
DoCovid-19 roundup: After promising US its summer supply, Gilead in talks with EU over remdesivir access; First inhaled remdesivir study underway
MiA new study points to $6.5B in public support building the scientific foundation of Gilead's remdesivir. Should that be reflected in the price?
MiZai Lab inks China deal with Turning Point with $25M upfront; Xencor, Atreca team up on bispecifics
MiSingular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs
MiConcert gets BTD for alopecia drug, setting up a late-stage showdown with giant rival Pfizer
Mi'Fundamentally different' from Portola, Dutch biotech lands €32M to steer anti-anticoagulant through the clinic
MiFDA bars the door - for now - against Merck's star cancer drug after Roche beat them to the punch
MiBiogen shares spike as execs complete a delayed pitch for their controversial Alzheimer's drug - the next move belongs to the FDA
MiCovid-19 roundup: EU backs Osivax's pursuit of a universal vaccine to fight Covid-19
MiMerck dangles up to $425 million to team with Flagship's Foghorn Therapeutics on drugging the shape of DNA
MiJohn Reed brings NK cells into Sanofi's CD38 rivalry with Darzalex - and offers thumbs up for Kiadis' new focus
MiGSK sets the stage for a toe-to-toe market showdown with Gilead's HIV champion Truvada
MiTrump and Navarro press again for hydroxychloroquine. Can the FDA stay independent?
DiBoehringer Ingelheim ties the knot with Numab on new antibodies; Cabaletta inks pact with Artisan
DiAlloVir tests how much an antiviral biotech can reap in a pandemic stock market